Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
- PMID: 17999080
- PMCID: PMC2668626
- DOI: 10.1007/s00430-007-0062-1
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
Erratum in
- Med Microbiol Immunol. 2008 Sep;197(3):335. Taylor, Mark J [added]
-
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.Med Microbiol Immunol. 2008 Sep;197(3):335. doi: 10.1007/s00430-007-0072-z. Med Microbiol Immunol. 2008. PMID: 27517272 Free PMC article. No abstract available.
Abstract
In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4-6 weeks, followed by ivermectin (IVM) after 6 months. After 6-27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
Figures



References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical